LQMT Liquidmetal Technologies (LQMT) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Chemicals & allied products · CIK 0001141240
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
3
13F, latest reported quarter
Liquidmetal Technologies insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
No insider purchases or sales are on record for LIQUIDMETAL TECHNOLOGIES INC in the period covered. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 79.8% of the 225,212,112 shares held after it.
- 1 other insider sold within 30 days.
- 3 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider Liquidmetal Technology Ltd sold about $28.8M of LQMT on Oct 10, 2024, the largest insider sale at the company on our record; 1 other insider sold within 30 days and 3 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 79.8% of the 225,212,112 shares held after it.
- 1 other insider sold within 30 days.
- 3 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Lugee Li Yeung Tak sold about $28.8M of LQMT on Oct 10, 2024, the largest insider sale at the company on our record; 1 other insider sold within 30 days and 3 funds added in the latest 13F quarter.Context
- 1 earlier Form 4 trade (code P or S) here by this insider (1 buy), the last on Nov 20, 2023.
- The trade is 14.6% of the 1,024,350 shares held after it.
- No other insider bought within 30 days.
- 3 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Executive Officer Chung Tony bought about $9.0K of LQMT on Nov 21, 2023; 3 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 90.2% of the 874,350 shares held after it.
- No other insider bought within 30 days.
- 3 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Executive Officer Chung Tony bought about $39.5K of LQMT on Nov 20, 2023, the largest insider purchase at the company on our record; 3 funds added in the latest 13F quarter.4 transactions on record · a thin record, read with care
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no House purchase disclosed in the last 12 months
Funds
3 funds bought in last quarter
Revenue
-8.8% year over year
below 65% of Pharma & Biotech
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
0.1% of the float short (float per yahoo 2026-10-26) · 1.0 days to cover · settled 2026-09-30
below 91% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch LQMT
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-40.0%12M
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns LQMT: institutional holders (13F)
13F holdings, latest reported quarter
620,307 sh
$123.1K
400,000 sh
$80.0K
$3.8K
250,000 sh
$50
Congress trades in LQMT
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
LQMT planned insider sales (Form 144)
No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows 3 funds added last quarter. Each figure is a federal filing, dated the day it went public.
LQMT financials
Revenue growth
-8.8%
XBRL, annual
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$665.0K
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM LQMT
| FY Dec 2025 | $784.0K |
| FY Dec 2024 | $860.0K |
| FY Dec 2023 | $510.0K |
| FY Dec 2022 | $383.0K |
| FY Dec 2021 | $811.0K |
| Jun 2026 | $196.0K |
| Mar 2026 | $256.0K |
| Dec 2025 | $176.0K |
| Sep 2025 | $37.0K |
| Jun 2025 | $289.0K |
| Mar 2025 | $282.0K |
| Dec 2024 | $129.0K |
| Sep 2024 | $316.0K |
At each fiscal year end
Single quarter
Net margin, TTM
n/a
revenue under $1M, the ratio says nothing
Net margin, TTM LQMT
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | -298.8% |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | -181.3% |
| Mar 2025 | -201.4% |
| Dec 2024 | n/a |
| Sep 2024 | -139.6% |
At each fiscal year end
Single quarter
Free cash flow, TTM
-$3.1M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM LQMT
| FY Dec 2025 | -$2.8M |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | -$349.0K |
| Mar 2026 | -$541.0K |
| Dec 2025 | -$1.4M |
| Sep 2025 | -$749.0K |
| Jun 2025 | -$280.0K |
| Mar 2025 | -$299.0K |
| Dec 2024 | -$1.0M |
| Sep 2024 | n/a |
At each fiscal year end
Single quarter
Debt to equity
0.00x
current debt only, 2017-12-31 (103 months older than the period end); equity 2026-06-30
Debt to equity LQMT
| FY Dec 2025 | 0.00x |
| FY Dec 2024 | 0.00x |
| FY Dec 2023 | 0.00x |
| FY Dec 2022 | 0.00x |
| FY Dec 2021 | 0.00x |
| Jun 2026 | 0.00x |
| Mar 2026 | 0.00x |
| Dec 2025 | 0.00x |
| Sep 2025 | 0.00x |
| Jun 2025 | 0.00x |
| Mar 2025 | 0.00x |
| Dec 2024 | 0.00x |
| Sep 2024 | 0.00x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
n/a
no debt to cover
Cash flow to debt LQMT
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
-10.6%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity LQMT
| FY Dec 2025 | -8.3% |
| FY Dec 2024 | -5.1% |
| FY Dec 2023 | -6.5% |
| FY Dec 2022 | -7.2% |
| FY Dec 2021 | -9.4% |
| Jun 2026 | -10.6% |
| Mar 2026 | -9.2% |
| Dec 2025 | -8.3% |
| Sep 2025 | -7.4% |
| Jun 2025 | -7.0% |
| Mar 2025 | -6.0% |
| Dec 2024 | -5.1% |
| Sep 2024 | -4.3% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-10.0%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets LQMT
| FY Dec 2025 | -7.9% |
| FY Dec 2024 | -4.9% |
| FY Dec 2023 | -6.3% |
| FY Dec 2022 | -6.9% |
| FY Dec 2021 | -9.1% |
| Jun 2026 | -10.0% |
| Mar 2026 | -8.7% |
| Dec 2025 | -7.9% |
| Sep 2025 | -7.1% |
| Jun 2025 | -6.7% |
| Mar 2025 | -5.7% |
| Dec 2024 | -4.9% |
| Sep 2024 | -4.1% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on invested capital LQMT
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
-16.0%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed LQMT
| FY Dec 2025 | -13.2% |
| FY Dec 2024 | -11.1% |
| FY Dec 2023 | -9.9% |
| FY Dec 2022 | -9.1% |
| FY Dec 2021 | -11.1% |
| Jun 2026 | -16.0% |
| Mar 2026 | -14.4% |
| Dec 2025 | -13.2% |
| Sep 2025 | -12.7% |
| Jun 2025 | -12.1% |
| Mar 2025 | -11.6% |
| Dec 2024 | -11.1% |
| Sep 2024 | -9.7% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
fewer than four consecutive quarters of diluted EPS
P/E, trailing LQMT
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$68.8M
market value at close 2026-10-27 on 2026-08-06 shares, plus current debt only, 2017-12-31 (103 months older than the period end), minus cash 2026-06-30
Enterprise value LQMT
| FY Dec 2025 | $84.6M |
| FY Dec 2024 | $30.7M |
| FY Dec 2023 | $46.2M |
| FY Dec 2022 | $52.8M |
| FY Dec 2021 | $78.2M |
| Jun 2026 | $175.2M |
| Mar 2026 | $93.5M |
| Dec 2025 | $84.6M |
| Sep 2025 | $119.9M |
| Jun 2025 | $104.5M |
| Mar 2025 | $68.5M |
| Dec 2024 | $30.7M |
| Sep 2024 | $41.0M |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
-4.0%
TTM free cash flow over market value at close 2026-10-27
FCF yield LQMT
| FY Dec 2025 | -3.0% |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | -1.7% |
| Mar 2026 | -3.0% |
| Dec 2025 | -3.0% |
| Sep 2025 | -1.8% |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
fewer than four consecutive quarters of diluted EPS
PEG, trailing LQMT
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-27. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $784.0K | $860.0K | $510.0K | $383.0K |
| Gross profit | $230.0K | $217.0K | $149.0K | $67.0K |
| Operating income | -$3.7M | -$3.3M | -$3.1M | -$3.1M |
| Net income | -$2.3M | -$1.5M | -$2.0M | -$2.4M |
| EPS (diluted) | n/a | n/a | 0.00 | 0.00 |
| Operating cash flow | -$2.8M | -$1.2M | -$1.3M | -$1.8M |
| Cash | $7.2M | $6.0M | $8.8M | $2.3M |
SEC XBRL, fiscal years, as known on 2026-10-28
LQMT Stock Sonar score 4/7 axes
Find similar shapesCompareLQMT ranks highest on financial health (99th percentile) and risk and compliance (90th), and lowest on growth (35th), among Pharma & Biotech peers.
4 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
